Screening of gene signatures for rheumatoid arthritis and osteoarthritis based on bioinformatics analysis

PEIHENG HE*, ZIJI ZHANG*, WEIMING LIAO, DONGLIANG XU, MING FU and YAN KANG

Department of Joint Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China

Received June 16, 2015; Accepted May 5, 2016

DOI: 10.3892/mmr.2016.5423

Abstract. The current study aimed to identify gene signatures during rheumatoid arthritis (RA) and osteoarthritis (OA), and used these to elucidate the underlying modular mechanisms. Using the Gene Expression Omnibus database, the present study obtained the GSE7669 mRNA expression microarray data from RA and OA synovial fibroblasts (n=6 each). The differentially expressed genes (DEGs) in RA synovial samples compared with OA samples were identified using the Linear Models for Microarray Analysis package. The Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed using the Database for Annotation Visualization and Integrated Discovery. A protein-protein interaction network was constructed and the modules were further analyzed using the Molecular Complex Detection plugin of Cytoscape. A total of 181 DEGs were identified by comparing RA and OA synovial samples (96 up- and 85 downregulated genes). The significant DEGs in module 1, including collagen, type I, α 1 (COL1A1), COL3A1, COL4A1 and COL11A1, were predominantly enriched in the extracellular matrix (ECM)-receptor interaction and focal adhesion pathways. Additionally, significant DEGs in module 2, including radical S-adenosyl methionine domain containing 2 (RSAD2), 2'-5'-oligoadenylate synthetase 2 (OAS2), myxovirus (influenza virus) resistance 1 (MX1) and ISG15 ubiquitin-like modifier (ISG15), were predominantly associated with immune function pathways. In conclusion, the present study indicated that RSAD2, OAS2, MX1 and ISG15 may be notable gene signatures in RA development via involvement in the pathways of ECM-receptor interactions and focal adhesions.

Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory disease which can lead to progressive disability, early mortality and other systemic complications (1). RA is incurable, has high socioeconomic costs and severely reduces the quality of life of patients (2). Osteoarthritis (OA) is the most common joint disease; it causes pain, disability and the loss of joint function (3). OA is also a chronic and incurable illness that lacks effective treatment strategies (4). Thus, advances in the understanding of the molecular mechanisms underlying these two diseases may lead to the development of novel therapeutic strategies.

RA is characterized by autoimmune and synovial inflammation, the destruction of multiple joints and the formation of pannus (5). OA is characterized by an inflammatory response and progressive breakdown of the articular cartilage of the joint (6). Genetic factors have been implicated in the development of these diseases (7,8). The human leukocyte antigen molecules and their relevant immunological pathways have been associated with RA pathogenesis (9). Sun et al (10) demonstrated that paired immunoglobin-like type receptor α was associated with inflammatory cell infiltration and was elevated in the synovial tissue from mice with RA. In addition, a genome-wide association and functional study suggests that DOT1-like histone H3K79 methyltransferase is associated with cartilage thickness and hip OA (11). Valdes et al (12) also confirmed that genetic variation in the SMAD family member 3 gene may result in the progression of hip and knee OA. Together, these findings indicate the importance of genetic mechanisms in the pathogenesis of RA and OA. Despite previous progress, the gene signatures associated with the pathogenesis of RA and OA remain unknown, and reliable predictive biomarkers for prognosis and treatment are lacking.

Microarray analyses have been increasingly used to identify disease-associated genes and pathways for elucidation of the molecular mechanisms of RA and OA (13,14). In a previous study, the GSE7669 microarray data was used to analyze differentially expressed genes (DEGs) between RA and OA using a gene co-expression network (15), or to screen candidate genes associated with RA by investigating core
and periphery interaction structures (16). By contrast, the current study used this microarray data and comprehensive bioinformatics methods to identify DEGs in synovial RA samples compared with OA samples. Additionally, the present study performed functional enrichment analysis for DEGs and functional module analysis of the protein-protein interaction (PPI) network. The current study aimed to identify important disease-associated genes and the molecular mechanisms involved in RA and OA.

Materials and methods

Affymetrix microarray data. The GSE7669 gene expression profile deposited by Pohlers et al (17) was downloaded from Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo/), which was based on the platform of Affymetrix Human Genome U95 Version 2 Array (Affymetrix, Inc., Santa Clara, CA, USA). This dataset included the gene expression profiles from the synovial fibroblasts of 6 patients with RA and 6 patients with OA.

Data preprocessing and DEG screening. All the raw expression data was preprocessed using the Affymetrix package (18) in R (cran.at.r-project.org) and Bioconductor (www.bioconductor.org), and the normalization was performed using the robust multiarray average algorithm (19). The gene expression matrix of samples was acquired.

DEGs in RA synovial samples compared with OA samples were identified using the Linear Models for Microarray Analysis (Limma; www.bioconductor.org/packages/release/bioc/html/limma.html) package (20) in R/Bioconductor. t-test in the Limma package was used to analyze the P-value of each gene symbol. Only DEGs with P<0.05 and |log2 fold change|>0.5 were considered to indicate a statistically significant difference.

Functional enrichment analysis of DEGs. Gene Ontology (GO; www.geneontology.org) (21) is widely used in biology for the collation of large-scale gene lists, including biological process (BP) ontology. The Kyoto Encyclopedia of Genes and Genomes (KEGG; www.genome.ad.jp/kegg) (22) is used for extracting the pathway information from molecular interaction networks. To understand the biological significance of DEGs, GO BP enrichment analysis and KEGG pathway analysis were performed using the Database for Annotation Visualization and Integrated Discovery (DAVID; david.abcc.ncifcrf.gov) online tool (23). The P<0.05 in the hypergeometric test and gene count >2 were defined as the cut-off values.

PPI network construction. The Search Tool for the Retrieval of Interacting Genes (STRING) (24) is a database providing information on experimentally verified and predicted protein interactions by calculating their combined score. Based on
the information of the STRING database, DEGs with the combined protein interaction score >0.4 were selected and used to construct a PPI network in the present study. Hub proteins (25) in the PPI network were identified based on connectivity degree analysis. The PPI network was visualized using Cytoscape software (www.cytoscape.org) (26).

Functional module analysis of PPI network. The functional modules of the PPI network were subsequently identified using the Molecular Complex Detection (MCODE) (27) plugin of Cytoscape. The parameters were set as follows: Degree cut-off, 2; node score cut-off, 0.2; K-core, 2; and max depth, 100. Functional enrichment analyses for DEGs in functional modules with higher degree and node scores were subsequently performed using the DAVID tool. P<0.05 and gene count >2 were considered to indicate a statistically significant difference.

Results

DEG screening. Comparing OA and RA samples, a total of 181 DEGs were obtained, in which 96 genes were upregulated in RA and downregulated in OA samples, and 85 genes were downregulated in RA and upregulated in OA samples.

Functional enrichment analyses. The GO BP terms and KEGG pathway analyses were conducted for functional annotation of the DEGs. The top 10 GO BP terms are presented in Table I. The results demonstrated that the upregulated genes were significantly enriched in functions associated with cell adhesion, biological adhesion and extracellular matrix (ECM) organization. Downregulated genes were predominantly associated with the regulation of cell death, and responses to hormone and endogenous stimuli.

In addition, 3 and 2 KEGG pathways were significantly enriched by up- and downregulated DEGs, respectively (Table II). The enriched KEGG pathways for the upregulated genes were ECM-receptor interactions, focal adhesions and the TGF-β signaling pathway, whereas the pathways enriched by the downregulated genes included the TGF-β signaling pathway and vascular smooth muscle contraction (Table II).

PPI network analysis. Based on the information of the STRING database, a total of 343 protein interactions with combined scores >0.4 were included in the PPI network (Fig. 1). The top 20 hub proteins were identified according to connectivity degree (Table III), including collagen type I α1 (COL1A1), COL1A2, COL3A1, COL4A2, integrin α1, COL4A1, biglycan and COL11A1. Notably, in addition to interferon-induced protein with tetratricopeptide repeats, these hub nodes were upregulated and the majority of them are collagen proteins.

Table II. The significantly enriched KEGG pathways.

| KEGG pathway term     | Description                                      | No. enriched genes | P-value       |
|-----------------------|--------------------------------------------------|--------------------|---------------|
| Upregulated           |                                                   |                    |               |
| hsa04512              | Extracellular matrix-receptor interaction         | 11                 | 3.77x10^-10   |
| hsa04510              | Focal adhesion                                    | 13                 | 1.60x10^-4    |
| hsa04350              | Transforming growth factor-β signaling pathway    | 4                  | 2.84x10^-2    |
| Downregulated         |                                                   |                    |               |
| hsa04350              | Transforming growth factor-β signaling pathway    | 4                  | 1.28x10^-2    |
| hsa04270              | Vascular smooth muscle contraction                | 4                  | 2.51x10^-2    |

KEGG, Kyoto Encyclopedia of Genes and Genomes.

Table III. The top 20 differentially expressed genes with higher connectivity degree in the protein-protein interaction network.

| Gene                                 | Degree |
|--------------------------------------|--------|
| Collagen, type I, α1                 | 28     |
| Collagen, type I, α2                 | 27     |
| Collagen, type III, α1               | 27     |
| Collagen, type IV, α2                | 22     |
| Integrin subunit α1                  | 17     |
| Collagen, type IV, α1                | 17     |
| Biglycan                             | 17     |
| Collagen, type XI, α1                | 16     |
| Versican                             | 15     |
| Collagen, type IV, α2                | 15     |
| Secreted protein, acidic, cysteine-rich| 15   |
| Periostin, osteoblast specific factor| 15     |
| Elastin                              | 13     |
| Cadherin 11                          | 12     |
| Interferon induced protein with tetratricopeptide repeats 1 | 12 |
| Fibromodulin                         | 12     |
| Collagen, type XIV, α1               | 12     |
| Interferon induced protein with tetratricopeptide repeats 3 | 11 |
| Collagen, type XV, α1                | 11     |
| Collagen, type XVI, α1               | 11     |

Functional module analysis of PPI network. In order to improve analysis of the PPI network, 5 modules were detected using the MCODE plugin. Only 2 module scores were >10 and the scores of other modules were not >3.5.
Module 1, with the highest node score (11.455), consisted of 12 nodes and 63 edges, in which upregulated genes, including COL3A1, COL4A1, COL1A1 and COL11A1 were included (Fig. 2A). Module 2 (node score=11) consisted of 11 nodes and 55 edges, in which the downregulated genes were included (Fig. 2B). The downregulated genes in module 2 included radical S-adenosyl methionine domain containing 2 (RSAD2), 2'-5'-oligoadenylate synthetase 2 (OAS2), myxovirus (influenza virus) resistance 1 (MX1) and ISG15 ubiquitin-like modifier (ISG15).

In addition, functional enrichment analyses for DEGs in the functional modules were performed. Module 1 was predominantly associated with the regulation of cell proliferation, response to wounding and wound healing (Table IV). Module 2 was predominantly associated with immune functions, including the response to viruses, defense response and immune response (Table IV). The significantly enriched pathways of module 1 were ECM-receptor interaction and focal adhesion, whereas, no pathways were significant for module 2 (Table IV).
Discussion

There is a lack of effective treatments for RA and OA, and exploring the gene signatures associated with the diseases may elucidate the molecular pathogenesis and provide opportunities for biomarker development. The results of the present study demonstrated that the significant DEGs of module 1, including COL3A1, COL4A1, COL1A1 and COL11A1, were predominantly enriched in the ECM-receptor interaction and focal adhesion pathways. Additionally, the DEGs of module 2, including RSAD2, OAS2, MX1 and ISG15, were predominantly associated with immune responses. All these DEGs and pathways may be important mechanisms in the development of RA and OA.

In a previous study, Olex et al. (28) identified the ECM-receptor interaction pathway to be an important signaling and metabolic pathway during the progression of OA. Koelling et al. (29) also demonstrated that several dysregulated genes in OA samples were associated with ECM-receptor interactions and focal adhesions. In the present study, DEGs, including COL3A1, COL4A1, COL1A1 and COL11A1, were predominantly enriched in the ECM-receptor interaction and focal adhesion pathways. It can, therefore, be speculated that the these pathways may contribute to OA progression. Additionally, COL3A1 is a gene important for cartilage function, and its expression was previously observed to be correlated with the radiographic severity of canine elbow OA (30). Cui et al. (31) demonstrated that COL3A1 expression was enriched in the focal adhesion pathway, which may suggest a molecular mechanism of OA. Furthermore, COL4A1 was previously identified as an OA-associated gene involved in the development of the disease (32). Gene expression analysis also indicated that COL1A1 was dysregulated in TGF-β-stimulated OA samples (33). COL11A1 was demonstrated to be an OA susceptibility gene in human joint tissues and is important in the development of this degenerative musculoskeletal disease (34). Additionally, a previous investigation demonstrated that multiple collagen genes (COL1A1, COL2A1, COL3A1 and COL4A1) were associated with the progression of OA (28). Collagen derivatives are candidates for disease-modifying OA drugs and are marketed as having therapeutic effects on reducing the symptoms of OA (35). Therefore, it is speculated that these collagens may be important gene signatures of OA and have implications in the progression of this disease through effects on ECM-receptor interactions and focal adhesions.

Furthermore, the innate immune response is understood to cause inflammation and joint destruction in RA, and a

### Table IV. The significantly enriched GO biological progress terms for modules.

| GO term          | Description                          | No. enriched genes | P-value       |
|------------------|--------------------------------------|--------------------|---------------|
| Module 1         |                                       |                    |               |
| 0042127          | Regulation of cell proliferation      | 12                 | 6.47x10^-10   |
| 0009611          | Response to wounding                  | 10                 | 4.98x10^-9    |
| 0042060          | Wound healing                         | 7                  | 1.89x10^-7    |
| 0001666          | Response to hypoxia                   | 7                  | 3.28x10^-7    |
| 0070482          | Response to oxygen levels             | 7                  | 4.70x10^-7    |
| 0009725          | Response to hormone stimulus          | 9                  | 4.75x10^-7    |
| 0031099          | Regeneration                          | 6                  | 8.12x10^-7    |
| 0009719          | Response to endogenous stimulus       | 9                  | 1.15x10^-6    |
| 0008284          | Positive regulation of cell proliferation | 8               | 1.20x10^-6    |
| 0001817          | Regulation of cytokine production     | 6                  | 3.26x10^-6    |
| Module 2         |                                       |                    |               |
| 0009615          | Response to virus                     | 5                  | 5.91x10^-8    |
| 0006952          | Defense response                      | 3                  | 2.74x10^-2    |
| 0006955          | Immune response                       | 3                  | 3.40x10^-2    |

GO, gene ontology.

### Table V. Significantly enriched KEGG pathways for modules.

| Term              | Description                  | Count | P-value |
|-------------------|------------------------------|-------|---------|
| Module 1          |                              |       |         |
| hsa04512          | ECM-receptor interaction      | 8     | 2.61E-13|
| hsa04510          | Focal adhesion                | 8     | 1.36E-10|

No significantly enriched pathways were identified for Module 2. Description represents the name of KEGG pathways and count represents the number of enriched genes. KEGG, Kyoto Encyclopedia of Genes and Genomes.
genome-wide association study has demonstrated that immune regulatory factors underlie this disease (36). Additionally, the potential of Tank-binding kinase 1 as a therapeutic target in RA suggests that there is an association between the synovio-cyte innate immune responses and RA development (37). McInnes and Schett (1) also investigated the importance of immune responses in the pathogenesis of RA. In the current study, GO functions associated with the immune response were enriched. Thus, the results of the present study support previous findings and suggest that immune responses may contribute to RA development.

Additionally, functional enrichment analysis performed in the present study demonstrated that DEGs in RA samples, including RSAD2, OAS2, MX1 and ISG15, were significantly enriched in the immune response pathway. RSAD2 is a type I interferon (IFN) response gene, and has been used in the clinic for the prediction of RA development (38,39). OAS2 is involved in the IFN β signaling pathway, and investigation of core and periphery interaction structures previously identified it as a candidate gene associated with RA (16). MX1 is also an IFN response gene and was previously demonstrated to be correlated with disease activity in fibroblast cells of RA synovial tissue (40). ISG15 sensitizes the IFN-activated JAK-STAT pathway, which is established to be important in RA development (41). Additionally, type I IFN has been demonstrated to enhance immune responses in vivo and acts as a signal linking innate and adaptive immunity (42). Smith et al (43) demonstrated that, as type I IFN signatures, RSAD2, OAS2 and MX1 may be important for predicting treatment response in RA. Therefore, the DEGs identified in the present study may be crucial gene signatures for elucidating the molecular pathogenesis of RA.

In conclusion, the results of the current study indicate that RSAD2, OAS2, MX1 and ISG15 may be RA gene signatures, and may be associated with RA development via effects on immune responses. COL3A1, COL4A1, COL1A1 and COL11A1 may be important gene signatures contributing to OA development via involvement in ECM-receptor interactions and focal adhesion. The present findings aid the clarification of periphery interactions previously identified it as a candidate gene associated with OA (44). The current study was supported by 5010 Clinical Research Project of Sun Yat-sen University (no. 20100005) and the National Natural Science Foundation of China (nos. 81371941 and 81301558).

Acknowledgements

The current study was supported by 5010 Clinical Research Project of Sun Yat-sen University (no. 20100005) and the National Natural Science Foundation of China (nos. 81371941 and 81301558).

References

1. McInnes IB and Schett G: The pathogenesis of rheumatoid arthritis. N Engl J Med 365: 2205-2219, 2011.

2. Wong JB, Ramey DR and Singh G: Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum 44: 2746-2749, 2001.

3. Loeser RF, Goldring SR, Scanzello CR and Goldring MB: Osteoarthritis: A disease of the joint as an organ. Arthritis Rheum 64: 1697-1707, 2012.

4. Wang HJ, Yu CL, Kishi H, Motoki K, Mao ZB and Miyaguchi A: Suppression of experimental osteoarthritis by adenovirus-mediated double gene transfer. Chin Med J (Engl) 119: 1365-1373, 2006.

5. Huber R, Hummert C, Gausmann U, Pohlers D, Koczlan D, Guthke R and Kinne RW: Identification of intra-group, inter-Individual, and gene-specific variances in mRNA expression profiles in the rheumatoid arthritis synovial membrane. Arthritis Rheum Ther 10: R98, 2008.

6. van den Berg WB: Osteoarthritis year 2010 in review: Pathomechanisms. Osteoarthritis Cartilage 19: 338-341, 2011.

7. Knevel R, Gröndal G, Huizinga TW, Visser AW, Jönsson H, Vikingsson A, Geirsson AJ, Steinson K and van der Helm-van Mil AH: Genetic predisposition of the severity of joint destruction in rheumatoid arthritis: A population-based study. Ann Rheum Dis 71: 707-709, 2012.

8. Bian Q, Wang YJ, Liu SF and Li YP: Osteoarthritis: Genetic factors, animal models, mechanisms, and therapies. Front Biosci (Elite Ed) 4: 74-100, 2012.

9. Bax M, van Heemst J, Huizinga TW and Toes RE: Genetics of rheumatoid arthritis: What have we learned? Immunogenetics 63: 455-466, 2011.

10. Sun Y, Caplazi P, Zhang J, Mazloom A, Kummerfeld S, Quinones G, Senger K, Lesch J, Peng I, Sebrell A, et al: PIRLo negatively regulates mouse inflammatory arthritis. J Immunol 193: 860-870, 2014.

11. Castaño Betancourt MC, Calleto F, Kerkhof HJ, Cornelis FM, Doherty SA, Hart DJ, Hofman A, Luiten FP, Macieczew RA, Mangino M, et al: Genome-wide association and functional studies identify the DOT1L gene to be involved in cartilage thickening and hip osteoarthritis. Proc Natl Acad Sci USA 109: 8218-8223, 2012.

12. Valdez AM, Spector TD, Tamm A, Kisand K, Doherty SA, Dennison EM, Mangino M, Tamm A, Kerna I, Hart DJ, et al: Genetic variation in the SMAD3 gene is associated with hip and knee osteoarthritis. Arthritis Rheum 62: 2437-2452, 2010.

13. Yoshida S, Arakawa F, Higuchi F, Ishibashi Y, Goto M, Sugita Y, Nomura Y, Nimo D, Shimizu K, Aoki R, et al: Gene expression analysis of rheumatoid arthritis synovial lining regions by cDNA microarray combined with laser microdissection: Up-regulation of inflammation-associated STAT1, IRF1, CXCL9, CXCL10, and CCL5. Scand J Rheumatol 41: 170-179, 2012.

14. Chanalaris A: Identification of a gene signature for osteoarthritis by comparing microarray data from rodent and human cartilage studies. Osteoarthritis Cartilage 22: S348-S349, 2014.

15. Lu QY, Han QH, Li X, Li ZC, Pan YT, Liu L and Fu QG: Analysis of differentially expressed genes between rheumatoid arthritis and osteoarthritis based on the gene co-expression network. Mol Med Rep 10: 119-124, 2014.

16. Singh S, Snijesh V and Venilla JJ: Rheumatoid arthritis candidate genes identification by investigating core and periphery interaction structures. In: Computational Intelligence in Medical Informatics. Muppalameni NB and Gunjan VK (eds). 1st edition. Springer-Verlag, Singapore, pp97-96, 2015.

17. Pohlers D, Beyer A, Koczlan D, Wilhelm T, Thiesen HJ and Kinne RW: Constitutive upregulation of the transforming growth factor-beta pathway in rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther 9: R95, 2007.

18. Gautier L, Cope L, Bolstad BM and Irizarry RA: Affy - analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20: 307-315, 2004.

19. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264, 2003.

20. Smyth GK: Limma: Linear models for microarray data. In: Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Gentleman R, Carey V, Huber W, Irizarry R, et al: Gene Ontology: Tool for the unification of biology. Nat Genet 25: 8 unleashed, 2000.

21. Kanehisa M and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Research 28: 27-30, 2000.
23. Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaie J, Stephens R, Baseler MW, Lane HC and Lempicki RA: The DAVID Gene Functional Classification Tool: A novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol 8: R183, 2007.

24. von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P and Snel B: STRING: A database of predicted functional associations between proteins. Nucleic Acids Res 31: 258-261, 2003.

25. He X and Zhang J: Why do hubs tend to be essential in protein networks? PLoS Genet 2: e88, 2006.

26. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504, 2003.

27. Bader GD and Hogue CW: An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics 4: 2, 2003.

28. Olex AL, Turkett WH, Fetrow JS and Loeser RF: Integration of gene expression data with network-based analysis to identify signaling and metabolic pathways regulated during the development of osteoarthritis. Gene 542: 38-45, 2014.

29. Koelling S, Kruegel J, Irmer M, Path JR, Sadowski B, Miro X and Miosge N: Migratory chondrogenic progenitor cells from repair tissue during the later stages of human osteoarthritis. Cell Stem Cell 4: 324-335, 2009.

30. Cui S, Zhang X, Hai S, Lu H, Chen Y, Li C, Tong P, Lu F and Yuan Z: Molecular mechanisms of osteoarthritis using gene microarrays. Acta Histochemica 117: 62-68, 2015.

31. Raine EV, Dodd AW, Reynard LN and Loughlin J: Allelic expression analysis of the osteoarthritis susceptibility gene COL11A1 in human joint tissues. BMC Musculoskeletal Disord 14: 85, 2013.

32. Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A, Kwiatkowski DP, McCarthy MI, Ouweland WH, Samani NJ, et al: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661-678, 2007.

33. Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, van de Wiel M, Dijkmans BA, Verweij CL and Voskuyl AE: The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther 4: R95, 2012.

34. Boyle DL, Soma K, Hodge J, Kavanagh A, Mandel D, Mease P, Shrumur R, Singhal AK, Wei N, Rosengren S, et al: The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis 74: 1311-1316, 2015.

35. Smith SL, Plant D, Eyre S and Barton A: The potential use of expression profiling: Implications for predicting treatment response in rheumatoid arthritis. Ann Rheum Dis 72: 1118-1124, 2013.